All News
MPO Antibodies Predict Relapses in MPO-ANCA-Associated Vasculitis
A study of MPO-ANCA positive patients followed serially over 2 years shows that reappearance of MPO‐ANCA may predict relapse in patients with MPO‐ANCA positive AAV and that routine MPO‐ANCA monitoring is warranted.
Read Article
The RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.
Read Article
The RheumNow Week in Review - Nonadherence and Astronomic Costs (5.11.18)
Dr. Jack Cush reviews highlights, news and journal articles from the past week on RheumNow.com.
Read Article
Severity of Lupus Nephritis is Declining over Time
A retrospective follow-up study of 499 lupus nephritis (LN) patients over three successive eras shows that LN has become less severe in recent years and thus, better long-term survival is possible.
Read Article
Mortality Risks Shift in Granulomatosis with Polyangiitis
Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here.
Read Article
The RheumNow Week in Review – Why Comorbidity is Like the Weather (5.3.18)
Dr. Jack Cush discusses the news and journal articles from the past week on RheumNow.com.
Read Article
The RheumNow Week in Review – FDA Showdown for Baricitinib (4.27.18)
Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.
Read Article
Fixed and Tailored Rituximab Regimens Equal in ANCA Associated Vasculitis
The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs).
Read Article
Lupus Subgroup Responds to Anti-CD22
The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.
Read Article
The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.
Read Article
Wear Your Pajamas to Work for Lupus
I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them.
Read ArticleRheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory SLE.
Read Article
SynBioSe: Combo Rituximab and Belimumab Succeeds in Severe Refractory Lupus
One of the driving pathogenic mechanisms in systemic lupus erythematosus (SLE) is the generation of immune complexes capable of inducing netosis (NET formation) and NET-derived DNA that may be an amplifying autoantigen and give rise to anti-nuclear autoantibodies (ANAs).
Read Article
Increased Comorbidity Burden in Lupus African Americans
Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, an
Read Article
Uveitis in JIA: Screen All, Treat Early
A European group of experts has formulated consensus-based recommendations for the treatment of juvenile idiopathic arthritis (JIA)-associated uveitis, focusing on screening, monitoring, and treatment of this potentially devastating extra-articular manifestation of JIA.
Read Article
Rituximab May Halt ILD in Antisynthetase Syndrome Myositis
A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most.
Read Article
The RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Read Article
The Consequences and Cure of Hepatitis C
I spent this past week seeing hepatitis C patients with our hepatologists, and being a rheumatologist, I was looking forward to seeing extra-hepatic manifestations of HCV that we read about in text-books - cryoglobulinemic vasculitis, sicca syndrome, porphyria cutanea tarda and many others. I suppose I should not be surprised that the week passed without seeing a single one of these.
Read Article
The RheumNow Week in Review - 23 March 2018
Dr. Jack Cush reviews the highlights from the news, journals and major meetings. New announcements and approval from the FDA; novel associations between ANCA vasculitis and thyroid disease; flare rates after arthroplasty; and pregnancy outcomes for men and women.
Read Article
mTOR Inhibition with Sirolimus Effective in Lupus
Lancet reports that 12 months of sirolimus treatment is associated with improvement in lupus disease activity presumeably by correction of pro-inflammatory T-cell activity.
Read Article
